Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-24-063080
Filing Date
2024-05-17
Accepted
2024-05-17 17:00:28
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2414794d1_defa14a.htm DEFA14A 17614
2 GRAPHIC tm2414794d1_defa14aimg01.jpg GRAPHIC 6229
3 GRAPHIC tm2414794d1_defa14aimg02.jpg GRAPHIC 3465
  Complete submission text file 0001104659-24-063080.txt   32562
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33357 | Film No.: 24961069
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)